---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-128686"
form_type: "8-K"
ticker: "ATOS"
cik: "0001488039"
company_name: "ATOSSA THERAPEUTICS, INC."
filed_at: "2024-11-19T23:59:59+00:00"
generated_at: "2026-05-29T22:28:00.956817+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Atossa Therapeutics enters at-the-market equity facility for up to $100M

## Summary
- Agreement with Jefferies LLC dated Nov 19, 2024 to sell up to $100M of common stock at-the-market.
- Commission to Jefferies is up to 3.0% of gross proceeds; company reimburses certain expenses.
- Proceeds intended for clinical development, working capital, and general corporate purposes.
- No obligation to sell any shares; company may suspend or terminate the agreement at any time.
- Shares registered under effective S-3 filed May 13, 2024; prospectus supplement filed Nov 19, 2024.

## SEC filing metadata
- accession: 0000950170-24-128686
- form_type: 8-K
- ticker: ATOS
- cik: 0001488039
- company_name: ATOSSA THERAPEUTICS, INC.
- filed_at: 2024-11-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1488039/000095017024128686/0000950170-24-128686-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1488039/000095017024128686/atos-20241119.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-128686
- JSON: https://secwatch.observer/filing/0000950170-24-128686.json
- Plain text: https://secwatch.observer/filing/0000950170-24-128686.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.